<h1 class="story-header">GlaxoSmithKline launches Africa charity partnership</h1>
<div class="caption body-narrow-width">
<span style="width:304px">New medicines will be sold at cost price with any profits reinvested in research</span>
</div>
<div class="story-feature related narrow">
<a class="hidden" href="http://www.bbc.co.uk/news/business-22476556#story_continues_1">Continue reading the main story</a> <h2>Related Stories</h2>
<ul class="related-links-list"><li>
<a class="story" rel="published-1367910933830" href="http://www.bbc.co.uk/news/world-africa-22430608">DR Congo 'worst place for mothers'</a>
</li><li>
<a class="story" rel="published-1356488211203" href="http://www.bbc.co.uk/news/uk-20842827">Africa image 'harming aid effort'</a>
</li></ul>
</div>
<p class="introduction" id="story_continues_1">Britain's biggest drug manufacturer has <a href="http://www.gsk.com/partnerships/save-the-children-partnership.html">launched a new partnership</a> with Save the Children to develop medicines to tackle child mortality in Africa.</p>
<p>GlaxoSmithKline and the charity said together they could save a million children's lives.</p>
<p>Save the Children chief executive Justin Forsyth said there was the potential for "huge gains".</p>
<p>But critics are wary about the close involvement of a pharmaceutical company in charitable work.</p>
<span class="cross-head">Stop infection</span>
<p>Save the Children admitted that its alliance with
GlaxoSmithKline would be controversial - but said the project would save
children's lives.</p>
<p>For example, a formula for mouthwash will be turned into a
gel that can be applied to the umbilical cords of babies to stop
infection.</p>
<p>The new medicines will be sold at cost price.</p>
<p>GlaxoSmithKline (GSK) said the partnership would set a new standard for how companies and charities could work together.</p>
<p>Initially, two flagship programmes will operate in DR Congo and Kenya.</p>
<p>These will be followed by other initiatives in Sub-Saharan Africa, Asia and Latin America.</p><span class="cross-head"></span>BBC international development correspondent Naomi
Grimley said critics questioned whether the pharmaceutical giant was
just after good publicity - and access to emerging economies that would
spend more on drugs in the future.